Market Size of Europe Neurostimulation Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 6.10 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Europe Neurostimulation Devices Market Analysis
The major factors for the growth of the European neurostimulation market include the growth in the geriatric population and rising prevalence of neurological disorders, increasing demand for minimally invasive surgeries, and technological advancements.
Among the age-related neurodegenerative disorders, Parkinson's disease (PD) is the second-most common, after Alzheimer's disease. According to NHS UK, Parkinson's disease affects around 1 in 500 people. Hence, there are an estimated 127,000 people in the United Kingdom, who are currently living with the condition. Most people with Parkinson's start to develop symptoms when they're over 50, although around 1 in 20 people with the condition, first experience symptoms when they're under 40. Furthermore, neurostimulation devices also play a significant role in pain management. In November 2018, Abbott announced the launch of the new DRG Invisible Trial System, which is approved by the US Food and Drug Administration (FDA) and has received the CE Mark in Europe. Thus, owing to the rising prevalence of neurological diseases and increasing technological advancements, the market is expected to witness high growth over the forecast period.
